Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Sources and structures of mitotic crossovers that arise when BLM helicase is absent in Drosophila.

LaFave MC, Andersen SL, Stoffregen EP, Holsclaw JK, Kohl KP, Overton LJ, Sekelsky J.

Genetics. 2014 Jan;196(1):107-18. doi: 10.1534/genetics.113.158618. Epub 2013 Oct 30.

2.

Asynchronous replication, mono-allelic expression, and long range Cis-effects of ASAR6.

Donley N, Stoffregen EP, Smith L, Montagna C, Thayer MJ.

PLoS Genet. 2013 Apr;9(4):e1003423. doi: 10.1371/journal.pgen.1003423. Epub 2013 Apr 4.

3.

An autosomal locus that controls chromosome-wide replication timing and mono-allelic expression.

Stoffregen EP, Donley N, Stauffer D, Smith L, Thayer MJ.

Hum Mol Genet. 2011 Jun 15;20(12):2366-78. doi: 10.1093/hmg/ddr138. Epub 2011 Mar 31.

4.

High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.

Loriaux MM, Levine RL, Tyner JW, Fröhling S, Scholl C, Stoffregen EP, Wernig G, Erickson H, Eide CA, Berger R, Bernard OA, Griffin JD, Stone RM, Lee B, Meyerson M, Heinrich MC, Deininger MW, Gilliland DG, Druker BJ.

Blood. 2008 May 1;111(9):4788-96. doi: 10.1182/blood-2007-07-101394. Epub 2008 Feb 5.

5.

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.

Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, Moseson EM, Wood LJ, Polakiewicz RD, Druker BJ, Deininger MW.

Mol Cell Biol. 2006 Aug;26(16):6082-93.

6.

Activating alleles of JAK3 in acute megakaryoblastic leukemia.

Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, Stoffregen EP, McGreevey L, Nardone J, Moore SA, Crispino J, Boggon TJ, Heinrich MC, Deininger MW, Polakiewicz RD, Gilliland DG, Druker BJ.

Cancer Cell. 2006 Jul;10(1):65-75.

7.

Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes.

Walters DK, Goss VL, Stoffregen EP, Gu TL, Lee K, Nardone J, McGreevey L, Heinrich MC, Deininger MW, Polakiewicz R, Druker BJ.

Leuk Res. 2006 Sep;30(9):1097-104. Epub 2006 Feb 7.

PMID:
16464493
8.

Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.

O'Hare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW, Druker BJ.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6987-93.

9.

A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib.

Crossman LC, O'Hare T, Lange T, Willis SG, Stoffregen EP, Corbin AS, O'Brien SG, Heinrich MC, Druker BJ, Middleton PG, Deininger MW.

Leukemia. 2005 Nov;19(11):1859-62.

PMID:
16151465
10.

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ.

Cancer Res. 2005 Jun 1;65(11):4500-5.

11.

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.

Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, Stoffregen EP, McWeeney S, Kovacs I, Park B, Druker BJ, Deininger MW.

Blood. 2005 Sep 15;106(6):2128-37. Epub 2005 May 24.

12.

RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518.

Walters DK, Stoffregen EP, Heinrich MC, Deininger MW, Druker BJ.

Blood. 2005 Apr 1;105(7):2952-4. Epub 2004 Dec 7.

13.

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.

Blood. 2004 Oct 15;104(8):2532-9. Epub 2004 Jul 15.

14.
15.

In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.

La Rosée P, Johnson K, Corbin AS, Stoffregen EP, Moseson EM, Willis S, Mauro MM, Melo JV, Deininger MW, Druker BJ.

Blood. 2004 Jan 1;103(1):208-15. Epub 2003 Aug 21.

16.

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib.

Corbin AS, La Rosée P, Stoffregen EP, Druker BJ, Deininger MW.

Blood. 2003 Jun 1;101(11):4611-4. Epub 2003 Feb 6.

17.

Supplemental Content

Loading ...
Support Center